Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study.
M PiazzaN M J HanssenF PerssonJ L ScheijenM P H van de WaarenburgM M J van GreevenbroekP RossingP HovindC D A StehouwerH-H ParvingMiranda T SchramPublished in: Diabetic medicine : a journal of the British Diabetic Association (2020)
Irbesartan treatment does not change plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone, free AGEs or d-lactate in type 2 diabetes. This indicates that increased dicarbonyls in type 2 diabetes are not targetable by ARBs, and other approaches to lower systemic dicarbonyls are needed in type 2 diabetes. (Clinical Trial Registry No: #NCT00317915).